

Maria Pia amato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772511/publications.pdf>

Version: 2024-02-01

285
papers

19,632
citations

9264

74
h-index

15266

126
g-index

294
all docs

294
docs citations

294
times ranked

10730
citing authors

#	ARTICLE	IF	CITATIONS
1	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1261-1267.	3.0	883
2	Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Multiple Sclerosis Journal</i> , 2012, 18, 891-898.	3.0	654
3	Cognitive Dysfunction in Early-Onset Multiple Sclerosis. <i>Archives of Neurology</i> , 2001, 58, 1602.	4.5	586
4	Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. <i>Journal of the Neurological Sciences</i> , 2006, 245, 41-46.	0.6	465
5	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	3.0	458
6	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 302-317.	10.2	437
7	The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006, 12, 787-793.	3.0	343
8	Cognitive Impairment in Early-Onset Multiple Sclerosis. <i>Archives of Neurology</i> , 1995, 52, 168.	4.5	329
9	Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. <i>Lancet Neurology</i> , The, 2020, 19, 860-871.	10.2	302
10	Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. <i>Neurology</i> , 2004, 63, 89-93.	1.1	293
11	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
12	Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. <i>BMC Neurology</i> , 2012, 12, 55.	1.8	275
13	The prevalence of pain in multiple sclerosis. <i>Neurology</i> , 2004, 63, 919-921.	1.1	274
14	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509.	2.5	254
15	New natural history of interferon- β -treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007, 61, 300-306.	5.3	251
16	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008, 70, 1891-1897.	1.1	251
17	Neuropsychological features in childhood and juvenile multiple sclerosis. <i>Neurology</i> , 2014, 83, 1432-1438.	1.1	227
18	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1258-1267.	3.0	209

#	ARTICLE	IF	CITATIONS
19	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529.	10.2	204
20	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1157.	4.5	203
21	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.1	201
22	Cognitive and psychosocial features in childhood and juvenile MS. <i>Neurology</i> , 2010, 75, 1134-1140.	1.1	198
23	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013, 260, 1452-1468.	3.6	189
24	Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 116-127.	3.0	186
25	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 779-788.	3.0	172
26	Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. <i>Neurology</i> , 2012, 78, 309-314.	1.1	169
27	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	2.5	166
28	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309903.	1.9	162
29	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1474-1482.	3.0	157
30	Cognitive impairment in early stages of multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 211-214.	1.9	153
31	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	3.0	148
32	Benign multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 1054-1059.	3.6	147
33	<sc>ECTRIMS</sc>/<sc>EAN</sc> guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	3.3	147
34	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010, 16, 62-67.	3.0	144
35	Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010, 75, 1794-1802.	1.1	142
36	Cognitive changes in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1585-1596.	2.8	141

#	ARTICLE	IF	CITATIONS
37	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	7.6	140
38	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011, 77, 145-150.	1.1	135
39	Real-life impact of early interferon β therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	5.3	132
40	Primary progressive multiple sclerosis involving ^From ^Radiologically ^Isolated ^Syndrome. <i>Annals of Neurology</i> , 2016, 79, 288-294.	5.3	130
41	Can the Expanded Disability Status Scale be assessed by telephone?. <i>Multiple Sclerosis Journal</i> , 2003, 9, 154-159.	3.0	123
42	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	2.5	122
43	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842.	3.0	115
44	Cognitive reserve and cortical atrophy in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1728-1733.	1.1	113
45	A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. <i>Journal of the Neurological Sciences</i> , 1999, 168, 96-106.	0.6	112
46	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009, 256, 1891-1898.	3.6	112
47	Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2009, 30, 15-20.	1.9	110
48	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	10.2	110
49	Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S74-81.	1.1	107
50	Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. <i>Neurology</i> , 2008, 71, 632-638.	1.1	104
51	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 91-98.	3.0	103
52	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.1	102
53	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
54	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	9.0	100

#	ARTICLE	IF	CITATIONS
55	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005, 11, 420-424.	3.0	99
56	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	1.8	99
57	Radiologically Isolated Syndrome: <sc>10-year</sc> Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417.	5.3	95
58	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
59	Meeting Review: The management of multiple sclerosis in children: a European view. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1258-1267.	3.0	91
60	Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. <i>Neurology</i> , 2009, 73, 498-503.	1.1	90
61	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 68-77.	3.0	89
62	A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. <i>Multiple Sclerosis Journal</i> , 2012, 18, 825-834.	3.0	89
63	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	1.9	88
64	Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 227-230.	1.9	87
65	Long-Term Adherence to Interferon β 2 Therapy in Relapsing-Remitting Multiple Sclerosis. <i>European Neurology</i> , 2008, 59, 131-135.	1.4	86
66	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 414.	9.0	86
67	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124.	1.8	82
68	Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. <i>PLoS ONE</i> , 2012, 7, e35843.	2.5	82
69	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002, 249, 152-163.	3.6	81
70	Evolving expectations around early management of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 351-367.	3.5	81
71	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 412-419.	3.0	78
72	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165.	1.8	78

#	ARTICLE	IF	CITATIONS
73	Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S82-7.	1.1	78
74	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e44826.	2.5	78
75	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 329-334.	3.0	77
76	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 214-221.	3.0	77
77	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015, 138, 3275-3286.	7.6	76
78	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. <i>Brain</i> , 2006, 129, 2008-2016.	7.6	75
79	Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2015, 29, 207-220.	5.9	75
80	Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 840-846.	1.9	74
81	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.1	74
82	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e19452.	2.5	74
83	Cortical lesions in radiologically isolated syndrome. <i>Neurology</i> , 2011, 77, 1896-1899.	1.1	73
84	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	3.0	73
85	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1225-1233.	3.0	72
86	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	2.3	71
87	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009, 30, 193-199.	1.9	68
88	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895.	1.1	68
89	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	5.3	67
90	Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S97-S102.	1.1	67

#	ARTICLE	IF	CITATIONS
91	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 845-850.	1.9	66
92	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013, 80, 2090-2094.	1.1	63
93	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63
94	Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis – Results of the BetaPlus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011, 307, 120-126.	0.6	59
95	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	1.9	59
96	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	3.5	58
97	Treatment of early-onset multiple sclerosis with intramuscular interferon-1a: long-term results. <i>Neurological Sciences</i> , 2007, 28, 127-132.	1.9	57
98	Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. <i>Neurological Sciences</i> , 2005, 26, s183-s186.	1.9	56
99	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 620-626.	3.0	56
100	Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. <i>PLoS ONE</i> , 2010, 5, e9287.	2.5	56
101	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 82, 1314-1321.	1.1	56
102	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 757-759.	1.9	55
103	Quantification of impairment in MS: discussion of the scales in use. <i>Multiple Sclerosis Journal</i> , 1999, 5, 216-219.	3.0	54
104	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013, 331, 94-97.	0.6	53
105	Subcutaneous Interferon 1a May Protect against Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. <i>PLoS ONE</i> , 2013, 8, e74111.	2.5	53
106	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	7.6	53
107	Reliability, practice effects, and change indices for Rao's brief repeatable battery. <i>Multiple Sclerosis Journal</i> , 2010, 16, 611-617.	3.0	52
108	Are there protective treatments for cognitive decline in MS?. <i>Journal of the Neurological Sciences</i> , 2006, 245, 183-186.	0.6	51

#	ARTICLE	IF	CITATIONS
109	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 214-219.	3.0	51
110	Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014, 35, 559-563.	1.9	51
111	Withdrawal of fingolimod treatment for relapsingâ€“remitting multiple sclerosis: report of six cases. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1636-1639.	3.0	50
112	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
113	Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 78-86.	4.1	48
114	Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1732-1740.	3.0	48
115	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	48
116	Impact of cognitive impairment on coping strategies in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 127-130.	1.4	47
117	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	1.8	47
118	Management options in multiple sclerosis-associated fatigue. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 207-216.	1.8	46
119	Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingâ€“remitting multiple sclerosis: a prospective, â€“nonâ€“randomized pilot study. <i>European Journal of Neurology</i> , 2013, 20, 986-990.	3.3	46
120	Influence of Apolipoprotein E Î¼4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 536.	4.5	45
121	Clinical outcome measures in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 118-122.	0.6	45
122	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449.	3.6	44
123	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011, 32, 1223-1231.	1.9	43
124	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive) Tj ETQq0 0 0 rg8.0/Overlock 10 Tf 50		
125	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
126	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 467-470.	1.9	42

#	ARTICLE	IF	CITATIONS
127	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. <i>Journal of Neuroscience</i> , 2015, 35, 550-558.	3.6	42
128	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
129	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1472-1480.	3.6	40
130	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon- β . <i>Journal of the Neurological Sciences</i> , 2006, 244, 97-102.	0.6	40
131	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 4180-4192.	3.6	40
132	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016, 23, 33-52.	1.4	39
133	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019, 40, 1651-1657.	1.9	39
134	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	3.0	39
135	Changes in Neuropsychological Test Performance Over the Workday in Multiple Sclerosis. <i>Clinical Neuropsychologist</i> , 2003, 17, 551-560.	2.3	38
136	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	3.0	38
137	Safety and tolerability of cyclophosphamide "pulses"™ in multiple sclerosis: a prospective study in a clinical cohort. <i>Multiple Sclerosis Journal</i> , 2003, 9, 446-450.	3.0	37
138	Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004, 25, s368-s370.	1.9	37
139	A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2009, 23, 268-275.	2.3	37
140	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014, 337, 67-73.	0.6	37
141	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37
142	Cognitive assessment in multiple sclerosis" an Italian consensus. <i>Neurological Sciences</i> , 2018, 39, 1317-1324.	1.9	37
143	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing"remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	3.0	36
144	"Subclinical MS"™: follow"up of four cases. <i>European Journal of Neurology</i> , 2008, 15, 858-861.	3.3	35

#	ARTICLE	IF	CITATIONS
145	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
146	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	5.3	34
147	Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. <i>Journal of Neurology</i> , 2007, 254, 220-227.	3.6	33
148	Improving Compliance with Interferon-Î² Therapy in Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2009, 23, 453-462.	5.9	33
149	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011, 32, 787-794.	1.9	33
150	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1234-1242.	3.0	33
151	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1741-1749.	3.0	32
152	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1627-1635.	3.0	32
153	Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. <i>PLoS ONE</i> , 2019, 14, e0222929.	2.5	32
154	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , 2022, 269, 5382-5394.	3.6	32
155	The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 472-478.	3.0	31
156	The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014, 35, 79-82.	1.9	31
157	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	1.8	31
158	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2022, 28, 132-138.	3.0	31
159	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	31
160	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	31
161	Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. <i>Multiple Sclerosis Journal</i> , 2006, 12, 281-286.	3.0	30
162	Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2006, 245, 195-199.	0.6	30

#	ARTICLE	IF	CITATIONS
163	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1326-1334.	3.0	30
164	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316.	1.9	30
165	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
166	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017, 38, 1849-1858.	1.9	30
167	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017, 8, 2216.	2.1	30
168	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020, 20, 204.	1.8	30
169	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359.	1.9	29
170	Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , 2011, 31, 295-297.	1.9	28
171	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640.	3.0	28
172	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004, 223, 69-71.	0.6	27
173	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN β exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 578-585.	3.0	27
174	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014, 14, 114.	1.8	27
175	Identifying risk factors for cognitive issues in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 333-347.	2.8	27
176	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	2.5	26
177	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , 2015, 85, 1722-1723.	1.1	26
178	Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 625-631.	2.9	26
179	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007, 13, 676-678.	3.0	24
180	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173.	3.0	24

#	ARTICLE	IF	CITATIONS
181	A 10-year follow-up of the European multicenter trial of interferon β -1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 533-543.	3.0	24
182	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
183	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. <i>Journal of the Neurological Sciences</i> , 2008, 266, 25-30.	0.6	23
184	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.6	23
185	Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. <i>Journal of Neurology</i> , 2013, 260, 1675-1677.	3.6	23
186	Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. <i>Neurological Sciences</i> , 2014, 35, 1895-1902.	1.9	23
187	The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011, 32, 1035-1041.	1.9	22
188	Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 94.	7.2	22
189	APOE- ϵ 4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1489-1494.	3.0	21
190	Cognitive impairment in pediatric multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 215-218.	1.9	21
191	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015, 21, 956-959.	3.0	21
192	Breastfeeding and post-partum relapses in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1211-1216.	3.0	21
193	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	3.0	21
194	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 39-51.	3.0	21
195	Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004, 25, s346-s349.	1.9	20
196	Truly benign multiple sclerosis is rare: let's stop fooling ourselves-Yes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 13-14.	3.0	20
197	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	1.9	20
198	No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1791-1796.	3.0	19

#	ARTICLE	IF	CITATIONS
199	International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016, 87, S110-6.	1.1	19
200	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. <i>Frontiers in Neurology</i> , 2017, 8, 608.	2.4	19
201	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	3.0	19
202	Cognitive Issues in Pediatric Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 442.	2.3	18
203	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group of the Italian Neurological Society. <i>Neurological Sciences</i> , 2011, 32, 351-358.	1.9	17
204	Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 683-692.	3.0	17
205	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963.	3.0	17
206	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020, 42, 3780-3792.	1.8	17
207	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020, 28, 236-246.	1.6	17
208	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021, 28, 149-160.	1.4	17
209	The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. <i>Journal of Autoimmunity</i> , 1990, 3, 587-592.	6.5	16
210	Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 481-485.	3.0	16
211	The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , 2009, 30, 163-165.	1.9	16
212	History of multiple sclerosis in 2 successive pregnancies. <i>Neurology</i> , 2016, 87, 1360-1367.	1.1	16
213	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 292-301.	3.0	16
214	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
215	Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. <i>European Journal of Neurology</i> , 2017, 24, 631-637.	3.3	15
216	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 3185-3193.	1.9	15

#	ARTICLE	IF	CITATIONS
217	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.1	15
218	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	14
219	MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e94794.	2.5	14
220	Donepezil for memory impairment in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 72-73.	10.2	13
221	Cognitive rehabilitation in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 275-278.	1.9	13
222	Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. <i>Neurological Sciences</i> , 2011, 32, 1043-1046.	1.9	13
223	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017, 89, 1265-1273.	1.1	13
224	Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 1011-1022.	5.3	13
225	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 645220.	2.4	13
226	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	3.0	13
227	Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2115-2126.	1.8	12
228	Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients. <i>European Neurology</i> , 2009, 61, 177-182.	1.4	12
229	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	3.3	12
230	Clinical correlations of CSF single IgG bands. <i>Journal of Neurology</i> , 2005, 252, 1274-1275.	3.6	11
231	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009, 2, 67-77.	3.5	11
232	ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009, 120, 439-441.	2.1	11
233	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS (COGIMUS) study. <i>BMC Neurology</i> , 2011, 11, 125.	1.8	11
234	Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 341, 28-31.	0.6	11

#	ARTICLE	IF	CITATIONS
235	Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008, 29, 235-237.	1.9	10
236	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011, 9, 42.	4.4	10
237	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308.	2.1	10
238	A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 1-2.	2.0	10
239	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	3.6	10
240	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1091-1100.	3.0	10
241	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	2.0	10
242	Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq0 0 0 rgBT.1 Overlook 10 Tf 50	1.0	10
243	A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 257-9.	1.0	9
244	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	4.4	9
245	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 787160.	2.4	9
246	Progress in multiple sclerosis â€” from diagnosis to therapy. <i>Nature Reviews Neurology</i> , 2018, 14, 72-74.	10.1	8
247	Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	7
248	Disease-modifying therapy aids cognition in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020, 16, 525-526.	10.1	7
249	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021, 27, 479-482.	3.0	7
250	Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. <i>Brain Sciences</i> , 2021, 11, 1341.	2.3	7
251	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.1	7
252	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the â€œbenign statusâ€? A 12-year follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 71-73.	2.0	6

#	ARTICLE	IF	CITATIONS
253	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	5.3	6
254	LONGITUDINAL FOLLOW-UP OF "BENIGN" MULTIPLE SCLEROSIS AT 20 YEARS. <i>Neurology</i> , 2007, 69, 938-939.1	1.1	5
255	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	1.0	5
256	Tracking cognitive impairment in multiple sclerosis using the Brain on Track test: a validation study. <i>Neurological Sciences</i> , 2020, 41, 183-191.	1.9	5
257	Current international trends in the treatment of multiple sclerosis in children" Impact of the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103277.	2.0	5
258	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016, 11, e0157721.	2.5	5
259	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. <i>Brain Sciences</i> , 2021, 11, 1444.	2.3	5
260	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210881.	3.0	5
261	Confounders in natural history of interferon" treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 126-126.	5.3	4
262	Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. <i>Journal of the Neurological Sciences</i> , 2009, 284, 223.	0.6	4
263	Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1243-1246.	2.8	4
264	Cognitive and Psychosocial Issues in Pediatric Multiple Sclerosis: Where We Are and Where We Need To Go. <i>Neuropediatrics</i> , 2012, 43, 174-175.	0.6	4
265	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	1.4	4
266	Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 61-66.	2.8	4
267	Maturation Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , 2017, 42, 299-308.	1.4	4
268	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
269	Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018, 91, 851-851.	1.1	4
270	A decline in cognitive function should lead to a change in disease-modifying therapy " Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1685-1686.	3.0	4

#	ARTICLE	IF	CITATIONS
271	COGNITIVE AND PSYCHOSOCIAL FEATURES OF CHILDHOOD AND JUVENILE MS. <i>Neurology</i> , 2009, 72, 1189-1190.	1.1	3
272	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , 2022, 28, 154-159.	3.0	3
273	Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. <i>PLoS ONE</i> , 2015, 10, e0135441.	2.5	3
274	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	3.0	3
275	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 403-403.	3.0	2
276	Cognitive dysfunction in pediatric-onset multiple sclerosis. , 0, , 134-143.		2
277	Cognitive dysfunction in multiple sclerosis: current approaches to clinical management. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 731-742.	2.8	1
278	The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1561-1563.	3.0	1
279	“Brain reserve” and “cognitive reserve” should always be taken into account when studying neurodegeneration” Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 577-578.	3.0	1
280	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107.	3.6	1
281	Understanding the pathophysiology of cognitive changes in MS: A step forward. <i>Multiple Sclerosis Journal</i> , 2021, 27, 4-5.	3.0	1
282	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEdiatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590.	1.0	1
283	Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. <i>Neurological Sciences</i> , 0, , .	1.9	1
284	Cognitive and Psychiatric Disorders in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010, , 147-158.	0.1	0
285	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β 1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101952.	2.0	0